Benitec Biopharma Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2021. Although the request metadata refers to 2020 Q4, this filing is an annual report for FY2021; it does not provide a standalone Q4 results breakdown. Amounts below are U.S. dollars unless noted.
Business context and development
Benitec is a development-stage biotechnology company developing DNA-directed RNA interference (ddRNAi) and “silence and replace” genetic medicines. Its lead candidate, BB-301, is an AAV gene therapy for oculopharyngeal muscular dystrophy (OPMD), designed to silence disease-causing PABPN1 and replace it with functional PABPN1. BB-301 has U.S. and EU orphan drug designations and remained in preclinical, IND-enabling development at year-end. BB-103, for chronic hepatitis B, was not actively being advanced; the company was seeking a strategic partner.
Benitec reported preliminary canine BB-301 pilot-study findings, based on analyses of 6 of 24 subjects, describing dose-dependent tissue transduction, gene expression and target-gene silencing. The study used a refined pharyngeal-muscle dosing method. Further analyses were ongoing. The company held a scientific advice meeting with France’s ANSM in May 2021 and planned to initiate a first-in-human OPMD study in 2022; that timing was an expectation, not a completed milestone. The prior BB-301 license and collaboration with Axovant had been terminated effective September 3, 2019, leaving Benitec responsible for development costs.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $59,000 | $102,000 |
| Research and development expense | $7.020 million | $3.001 million |
| General and administrative expense | $6.512 million | $5.567 million |
| Total operating expenses | $13.655 million | $8.383 million |
| Net loss | $13.882 million | $8.274 million |
| Net cash used in operating activities | $12.832 million | $7.535 million |
| Cash and cash equivalents at year-end | $19.769 million | $9.801 million |
- Revenue was immaterial and came from licensing, royalty and service activity; there were no product sales. FY2021 revenue was licensing revenue, while FY2020 included $93,000 of royalty revenue, $4,000 of service revenue and $5,000 of government grants.
- Operating expenses rose about 63%, driven chiefly by higher BB-301 preclinical and stock-based compensation costs. G&A also increased, including insurance, consulting, legal and accounting costs. The FY2020 royalties and license-fees line was a $185,000 credit from an accrual reversal; FY2021 expense was $123,000.
- FY2021 basic and diluted loss per share was $3.23, compared with $8.10 in FY2020. Weighted-average shares increased to 4.295 million from 1.021 million, so the per-share comparison reflects substantial dilution as well as the loss.
- Financing activities provided $22.522 million net in FY2021, including two public offerings. The October 2020 offering generated about $9.9 million net and the April 2021 offering about $12.7 million net. Cash from operations and investing activities totaled $13.053 million used.
- The company reported no borrowings and no credit facility. Year-end current assets were $20.608 million and current liabilities $1.369 million; lease liabilities were $213,000, all current. Accumulated losses were $130.1 million. No gross-margin measure is meaningful given the absence of product sales and minimal revenue.
- Management estimated cash would fund operations for at least 12 months after the September 20, 2021 filing date, but stated additional funding would be needed to initiate and complete BB-301 clinical studies. The estimate depends on assumptions and the operating plan.
Material changes, outlook and risks
- Revenue fell 42% year over year, while net loss widened by $5.608 million and operating cash use increased by $5.297 million. R&D expense more than doubled.
- Shares outstanding increased from 1.108 million at June 30, 2020 to 8.172 million at June 30, 2021, primarily reflecting equity offerings and warrant exercises. Additional financing may dilute shareholders or impose restrictive terms.
- COVID-19 delayed the start of BB-301 tissue-transduction work by several months and reduced laboratory work during work-from-home measures. The company said it would continue to reassess effects on timelines, costs, vendors and financing access.
- Key risks include preclinical failure or safety issues, AAV delivery and immune-response limitations, regulatory uncertainty for gene therapy, dependence on third-party manufacturers and study providers, limited internal resources, intellectual-property and licensing risks, and the need for additional capital. There is no assurance that any candidate will reach trials or be approved.
- Manufacturing is outsourced; the company had no long-term manufacturing agreement. It reported no material legal proceedings or contingent liabilities. The independent auditor issued an unqualified opinion on the financial statements; the auditor did not attest to internal-control effectiveness, as the company relied on the non-accelerated-filer exemption.
Important facts for investors to verify
- Whether subsequent BB-301 pilot-study analyses and the full 24-subject dataset confirm the preliminary findings, and whether the GLP toxicology, manufacturing and clinical plans support the stated first-in-human timetable.
- Current cash, operating burn and financing runway, including the amount and terms of any funding needed to commence and complete clinical studies.
- Share dilution from offerings, outstanding warrants and options, and any subsequent securities issuances.
- Whether BB-103 attracts a partner and whether Benitec’s licensing arrangements generate meaningful future revenue.
- How COVID-19, AAV-related safety and immune risks, manufacturing capacity, regulatory feedback and intellectual-property rights affect development milestones and costs.